Biogen Completes Acquisition of Apellis, Secures $2B Loan, CVR Agreement in Place

SEC 8-K Filing Notice

Company: Biogen Inc. (BIIB) Filing Date: 2026-05-14 Accession Number: 0001193125-26-222908

Items Filed

Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 2.03: Creation of a Direct Financial Obligation Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

Biogen (BIIB) announced the completion of its acquisition of Apellis Pharmaceuticals on May 14, 2026. The acquisition was finalized following a successful tender offer where Biogen acquired approximately 82.4% of Apellis' outstanding shares. As part of the deal, Biogen has established a Contingent Value Rights (CVR) agreement, offering CVR holders the potential to receive up to $4.00 per share based on the future sales performance of SYFOVRE and related products. The acquisition strengthens Biogen's portfolio, particularly in the ophthalmology space, with SYFOVRE, a key product from Apellis.

Key Takeaways

Biogen completes acquisition of Apellis Pharmaceuticals.
Tender offer successful: Biogen acquires 82.4% of Apellis shares.
Contingent Value Rights (CVR) agreement established, offering up to $4.00 per share based on SYFOVRE sales milestones.
Biogen secures $2 billion in term loan facilities to finance the acquisition.
Merger completed without a vote of Apellis stockholders.

Analysis

The completion of the Apellis acquisition marks a significant strategic move for Biogen, expanding its presence in the growing ophthalmology market. The CVR structure provides Apellis shareholders with potential upside based on the commercial success of SYFOVRE, aligning interests and potentially mitigating concerns about the acquisition price. For investors, the success of the acquisition hinges on Biogen's ability to effectively integrate Apellis and drive sales of SYFOVRE. Competitors in the ophthalmology space will be closely watching Biogen's execution, as the acquisition could reshape the competitive landscape. The $2 billion loan adds debt to Biogen's balance sheet, which investors will also be monitoring.

This post was automatically generated from an SEC 8-K filing.